Dyadic Logo Current.jpg
Dyadic Reports 2023 Full Year Results and Recent Company Progress
March 28, 2024 16:00 ET | Dyadic International, Inc.
Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from First-In-Human Phase 1 trial demonstrated clinical...
TENAX_RGB.png
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
March 28, 2024 08:30 ET | Tenax Therapeutics
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion...
DareBio_Stacked_Fullcolor_RGB.jpg
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
March 28, 2024 08:00 ET | Daré Bioscience, Inc.
2023 Highlights and Anticipated 2024 Milestones XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription in the United States to treat bacterial vaginosis under license agreement...
Matinas BioPharma
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
March 27, 2024 16:05 ET | Matinas BioPharma Holdings, Inc.
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded...
New Logo.png
Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium
March 27, 2024 08:00 ET | Provectus Biopharmaceuticals Inc.
New Provectus Spinout Company Would Commercialize Combination Therapy of University’s Light Source Medical Device and Provectus’s Pharmaceutical-Grade Rose Bengal Sodium KNOXVILLE, TN, March 27,...
EDAP-TMS_RGB-300dpi-20160111.png
EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results
March 27, 2024 07:00 ET | EDAP TMS S.A.
Record Q4 2023 total revenue of EUR 19.6 million ($21.3 million USD) increased 24.8% over Q4 2022Record Q4 2023 HIFU revenue of EUR 7.5 million ($8.1 million USD), an increase of 38.8% over Q4...
Logo.png
Food Allergy Treatment Drug Market to Register Immense Growth by 2032, Assesses DelveInsight | Key Companies - Vedanta Biosciences, Novartis, Alladapt Immunotherapeutics, Regeneron Pharmaceuticals, Genentech, Parexel
March 26, 2024 13:00 ET | DelveInsight Business Research LLP
New York, USA, March 26, 2024 (GLOBE NEWSWIRE) -- Food Allergy Treatment Drug Market to Register Immense Growth by 2032, Assesses DelveInsight | Key Companies - Vedanta Biosciences, Novartis,...
BrainBox AI introduces ARIA
BrainBox AI Introduces ARIA: The World’s First Generative AI-Powered Virtual Building Assistant
March 26, 2024 06:00 ET | BrainBox AI Inc
MONTREAL, March 26, 2024 (GLOBE NEWSWIRE) -- BrainBox AI, a pioneer in building technology, today announced the launch of the world’s first virtual building assistant, ARIA (Artificial Responsive...
 Valneva Initiates P
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
March 26, 2024 02:00 ET | VALNEVA
Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the ...
Landos (1).jpg
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
March 25, 2024 08:30 ET | Landos Biopharma, Inc.
NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement...